Search
Close this search box.
Search
Close this search box.
June 24, 2015

Drug Caucus Hearing on Barriers to Cannabidiol Research

The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy.

Opening Statements

CHAIRMAN (R - IA)

Chuck Grassley

Sen. Grassley’s opening statement, as prepared for delivery.

CO-CHAIR (D - CA)

Dianne Feinstein

Sen. Feinstein’s opening statement, as prepared for delivery.

Witnesses

Deputy Assistant Administrator of Drug Diversion with the Drug Enforcement Administration (DEA), Washington, D.C.

Deputy Director for the Center for Drug Evaluation and Research, Food and Drug Administration, Washington, D.C.

Director, National Institute on Drug Abuse, Washington, D.C.

Panel II

Child Neurologist, University of Mississippi Medical Center, Jackson, Mississippi

Emergency Room Physician, Arrowhead Regional Medical Center, Colton, California

Co-Founder, Project SAM (Smart Approaches to Marijuana), Cambridge, Massachusetts